News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase I (World)
Can-Fite BioPharma (CFBI) To Present At BIO CEO & Investor Conference In New York City On February 8, 2016 2/5/2016
Lab Criticized as 'Slow to React' in Bial's Fatal Drug Trial 2/5/2016
Nordic Nanovector To Present At The Swiss-Scandinavian Bio-Business Seminar On 10 February 2016 2/5/2016
ERYtech Pharma To Present At Upcoming Investor Conferences 2/4/2016
Kamada Ltd. (KMDA) Reports 2015 Fourth Quarter And Full Year Financial Results 2/2/2016
Mymetics Announces Discontinuation of the RSV Collaborative Project 1/29/2016
Affimed Therapeutics AG (AFMD) Enters Into Collaboration With Merck & Co. (MRK) To Evaluate AFM13 In Combination With KEYTRUDA (Pembrolizumab) For Patients With Hodgkin Lymphoma 1/25/2016
CARsgen Therapeutics Completes $30 Million Series B Financing 1/25/2016
Oncolytics Biotech Inc. (ONC.TO) Announces First Patients Treated In Phase 1b Study In Advanced Pancreatic Cancer 1/20/2016
Questions Remain as to What Caused the Bial Trial Tragedy in France 1/20/2016
Man in Coma Dies After Bial's Botched Drug Trial in France, Five Remain Hospitalized 1/19/2016
Drugmaker Unnamed as Botched Trial in France Leaves One Patient Brain Dead and Five Hospitalized 1/18/2016
Apogenix Receives First Milestone Payment From CANbridge Licensing Agreement And Signs Amendment To Include Taiwan 1/7/2016
CANbridge Completes Chinese Glioblastoma Biomarker Study For Lead Candidate, CAN008 1/7/2016
Sensorion Receives Approval From The UK Drug Agency To Initiate Clinical Trial Of SENS-218 1/6/2016
Rhythm And Camurus Announce License Agreement For Extended Release Fluidcrystal Setmelanotide 1/5/2016
BioLineRx Ltd. To Present At Biotech Showcase 2016 Conference In San Francisco 1/4/2016
Cellprothera Release: Cellular Regenerative Therapy Greeted By French Minister Of Health 1/4/2016
HUYA Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan 12/22/2015
CSL Behring Submits Marketing Authorization Application To The European Medicines Agency For RViii-SingleChain For Patients With Hemophilia A 12/22/2015
Flamel Technologies (FLML) Announces Positive Interim Results Of A First-In-Man Clinical Trial With MedusaExenatide 12/22/2015
Entia Biosciences Begins Clinical Study Of Proprietary Ergod2 Medical Food Product To Demonstrate Improved Health For The More Than 25 Million Chronic Kidney Disease Sufferers In The U.S. 12/21/2015
DS Biopharma Announces Successful Completion Of A Phase I Safety Study With Bioactive Lipid DS102 Which Is Targeting NASH And IPF 12/18/2015
Akaal Pharma Announces Superior Safety And Comparable Efficacy Of Sphingosine 1-Phosphate Receptor-1 (S1P1) Modulator AKP-11 As Compared To Gilenya (Fingolimod) For The Treatment Of Multiple Sclerosis 12/14/2015
Bayer (BAY) Looks to Become Player in Oncology Treatments 12/14/2015
AstraZeneca PLC (AZN)'s New R&D Approach Involves Diving into the Secretome 12/14/2015
Kadimastem Reached Agreements With The FDA Regarding The Framework Of The Clinical Trials In Humans For The Treatment Of ALS 12/10/2015
CollPlant Reports Positive Interim Trial Results For VergenixSTR, Indicated For The Treatment Of Tendinopathy 12/8/2015
Beigene Presents Clinical Data For BTK Inhibitor BGB-3111 At 57th American Society of Hematology Annual Meeting 12/8/2015
Akari Therapeutics Announces Update From Non-Human Primate Safety Study At International PNH Interest Group 10th Annual Scientific Meeting 12/7/2015
ADC Therapeutics Receives FDA Clearance To Begin Clinical Studies For Its Second Novel Antibody Drug Conjugate ADCT-402 Against Lymphomas And Leukemia 12/4/2015
Celyad Treats First Patient Of Second Cohort In NKG2D CAR T-Cell Phase I Trial 12/1/2015
SELLAS Life Sciences Reports Positive WT1 Cancer Vaccine Clinical Results In Mesothelioma And Acute Myeloid Leukemia (AML) Patients At The Annual International WT1 Conference 11/30/2015
Adocia Announces Positive Phase 1b Results Of BioChaperone Combo In Patients With Type 2 Diabetes 11/25/2015
ESSA Pharma Announces Enrollment Of First Patient In Phase 1/2 Trial 11/25/2015
BioLineRx Ltd. To Host Investor Breakfast In New York On December 3, 2015 11/25/2015
Autifony Therapeutics Initiates Phase I Study Of AUT00206, A Novel Treatment Approach For Schizophrenia 11/25/2015
Novogen Limited (NVGN) Engages Contract Research Organisation To Conduct Cantrixil Phase 1 Clinical Trial 11/24/2015
Cobra Biologics Ltd. Appointed By University of Sheffield To Advance Novel Fusion Protein Technology Into Phase 1 Clinical Trials 11/23/2015
Nitto Denko Corporation (XETRA: ND5.DE)'s ND-L02-S0201:Rnai Anti-Fibrosis Drug For The Treatment Of Liver Fibrosis Granted FDA Fast Track Designation 11/20/2015
AmpliPhi Biosciences Corporation (APHB) Signs Clinical Trial Agreement With University of Adelaide To Conduct A Phase I Trial Of Bacteriophage Therapy For Treating Staphylococcus Aureus Infections 11/19/2015
Allergan (AGN) Release: Positive Phase I/II Interim Data Of Bimatoprost Sustained-Release Implant For IOP Therapy In Glaucoma 11/16/2015
Turing Pharma Initiates Dosing In Phase I Clinical Trial Of TUR-004 For Epileptic Encephalopathies 11/16/2015
DelMar Pharma Presents Data Summarizing The Potential Of VAL-083 As A New Treatment Option For Resistant Cancers 11/13/2015
Novogen Limited (NVGN) Patent Covering Cantrixil And Trilexium Accepted In Australia 11/12/2015
Allergan (AGN) Presents Data At The 2015 American Academy of Ophthalmology Annual Meeting In Las Vegas 11/12/2015
ORYZON Genomics Announces First Patient Dosed In Phase I Extension Cohort Of ORY-1001 11/10/2015
NuCana Presents Exciting Data On Novel Anticancer Agent, NUC-3373, At The AACR-NCI-EORTC Conference In Boston 11/9/2015
Mallinckrodt (MNK) Study Shows Acthar Reduces Disease Activity In Patients With Persistently Active Systemic Lupus Erythematosus 11/9/2015
DS Biopharma Obtains A Granted Patent Covering The Use Of DS102 To Treat Fatty Liver Disorders 11/9/2015
Hutchison China MediTech (Chi-Med) Initiates Sulfatinib U.S. Clinical Trials 11/6/2015
Cynata Engages CRO To Conduct GvHD Clinical Trial 11/5/2015
ESSA Pharma Receives Health Canada Approval To Commence Clinical Development For EPI-506 11/5/2015
Oncolytics Biotech Inc. (ONC.TO) Announces 2015 Third Quarter Results 11/5/2015
DelMar Pharma To Present At The SeeThruEquity Microcap Investor Forum On November 12, 2015 11/5/2015
Adocia Announces Positive Phase 1b Results On The Post-Meal Effect Of BioChaperone Combo In Patients With Type 1 Diabetes 11/4/2015
Debiopharm Presents Positive Preliminary Results From Phase 1 Trials In The Development Of The IAP Inhibitor Debio 1143 At The 27th EORTC-National Cancer Institute-AACR Symposium In Boston 11/3/2015
Jenner Institute at Oxford University Release: Potential New Vaccine Candidate Aims To Block Transmission Of Malaria Parasites 11/2/2015
Hutchison China MediTech (Chi-Med) Release: Completion Of Phase I Clinical Trial Of Novel Syk Inhibitor HMPL-523 For Autoimmune Diseases In Healthy Volunteers 10/30/2015
Astellas (ALPMY) Inititaties Phase 3 Registration Trial Of gilteritinib (ASP2215) In Relapsed Or Refractory Acute Myeloid Leukemia Patients 10/28/2015
The World’s Largest Clinical Study Is Examining the World’s Oldest Wonderdrug, National Institute for Health Research Reveals 10/27/2015
Living Cell Technologies Ltd. Data Shows NTCELL Treatment Has Stopped The Progression Of Parkinsons 10/27/2015
Blaze Bioscience Inc. Announces Presentation At GAC-SC 2015 Conference 10/27/2015
RedHill Biopharma Ltd. (RDHL) Announces Positive Top-Line Results From YELIVA (ABC294640) Phase I Study In Advanced Solid Tumors 10/26/2015
Aprea Presents Preliminary Clinical Phase Ib/II Results In Ovarian Cancer With APR-246 – A ‘First-In-Class’ Compound Reconverting Mutant To Wild-Type P53 Protein 10/23/2015
Hutchison China MediTech (Chi-Med) Release: Proof-Of-Concept Study Of Fruquintinib In Non-Small Cell Lung Cancer Triggers Milestone Payment 10/23/2015
ERYtech Pharma Announces Publication Of Two Articles Describing Clinical Results With ERY-ASP/GRASPA 10/21/2015
Cormorant Pharmaceuticals Release: Decision Taken To Escalate To The Next Dose Level In A Clinical Trial With Humax-IL8 In Patients With Advanced Solid Tumors Ongoing At The National Cancer Institute 10/21/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Phase 1b Study In Advanced Pancreatic Cancer 10/20/2015
First Participants Enrolled In Replicel Life Sciences's Phase 1 Clinical Trial Of Its RCS-01 Dermatology Injectable 10/20/2015
Ability Pharmaceuticals Announces Positive Phase 1/1b Study Results Of ABTL0812 In Cancer Patients With Advanced Solid Tumors 10/20/2015
Protalix Biotherapeutics, Inc. (PLX) Reports Positive Long Term Data On PRX-102 For Fabry Disease 10/19/2015
AstraZeneca PLC (AZN) Halts Two Lung Cancer Drug Combination Trials After Lung Disease Reports 10/13/2015
BeiGene Co.,Ltd Doses First Patient In China With BGB-283 For Solid Tumors 10/12/2015
3SBio Inc. (SSRX) Signs Exclusive Patent License Agreement For ALT-P7, An Antibody-Drug Conjugate Targeting HER2 With Alteogen 10/12/2015
CollPlant Announces Completion Of Patient Recruitment For Clinical Trial Of VergenixFG (Flowable Gel) For The Treatment Of Chronic Wounds 10/7/2015
Ascend Announces Patients With Nodular Basal Cell Carcinoma Receives First Dose Of ASN-002 In Phase 1/2a Study 10/7/2015
Summit Therapeutics Presents Additional Data From Phase Ib Modified Diet Clinical Trial Of SMT C1100 In DMD Patients At WMS 9/30/2015
DelMar Pharmaceuticals To Present Data On The Promising Potential Of VAL-083 In The Treatment Of Pediatric Brain Tumors 9/29/2015
Aduro Biotech (ADRO) Announces Phase 1b Mesothelioma Trial Featured In Spotlight Poster At ESMO/ECC 9/28/2015
RXi Pharmaceuticals (RXII) Granted Patent In China For Lead Clinical Candidate RXI-109 9/28/2015
TiGenix Release: AlloCSC-01 Phase I Data Presented At The Congress Of European Society of Cardiology 9/23/2015
Pharmaxis (PXS.AX) Releases Successful Results Of Phase 1 Clinical Trial For Boehringer Ingelheim Partnered Drug PXS-4728A 9/22/2015
Pluristem Therapeutics (PSTI) and National Institute of Allergy And Infectious Diseases (NIAID) Complete FDA Meeting on PLX-R18 Cells in ARS 9/21/2015
uniQure (QURE) Release: Positive Topline Results Announced From Phase I/II Trial In Sanfilippo B Syndrome Patients Using Uniqure's Novel AAV5-Based Gene Therapy 9/21/2015
BerGenBio AS Release: BGB324 Enhances Immune Checkpoint Inhibitor Efficacy In Preclinical Cancer Models 9/21/2015
Bionomics Limited (BNO.AX) Reports Positive Data From Phase 1 Multiple Ascending Dose Trial Of BNC210 For Anxiety And Depression 9/16/2015
Benitec (BLT.AX) Initiates A Fourth Site In Hepatitis C Clinical Trial 9/16/2015
EnGeneIC Pty Ltd To Initiate U.S. Phase 1 Clinical Study Using Targeted EDV Nanocells To Treat Advanced Glioma Patients 9/16/2015
Transition Therapeutics Inc. (TTH.TO) Announces Fiscal 2015 Financial Results 9/16/2015
Cellular Biomedicine Group (CBMG) To Present CAR-T Phase I Clinical Trial Data For Non Small Cell Lung Cancer And Other Solid Tumors At 5th World Congress On Cancer Therapy 9/16/2015
Glenmark Pharmaceuticals's Bi-Specific Antibody - GBR 1302 To Enter Phase I Trials 9/15/2015
Celyad Announces the Appointment Of Dr. Frederic Lehmann As Vice President Immuno-Oncology 9/15/2015
Replicel Life Sciences Announces Initiation Of Clinical Site And Participant Recruitment For European Skin Aging Study 9/15/2015
Oryx Pharmaceuticals, Inc. Enrolls First Patients In An Additional Phase I Trial With Therapeutic Vaccine Vicoryx To Treat HPV-Associated Cancers In Combination With Standard Chemotherapy 9/15/2015
ProQR Therapeutics B.V. (PRQR) Announces A Proof-Of-Concept Nasal Potential Difference Study Of QR-010 Is Open For Enrollment 9/14/2015
Cellular Biomedicine Group (CBMG) To Release CAR-T For Non-Small Cell Lung Cancer Phase I Clinical Trial Data At 2015 European Cancer Congress 9/14/2015
Merck KGaA (MKGAF.PK), Darmstadt, Germany And Pfizer (PFE) To Present Updates For Avelumab At The European Cancer Congress 2015 9/11/2015
Neovacs SA Confirms Potent And Long-Lasting Biological Activity Of IFNa-Kinoid 4 Years After Patient Dosing In Phase I/IIa Trial 9/9/2015
Protalix Biotherapeutics, Inc. (PLX) Reports Positive Phase I/II Interim Clinical Data On The 1mg/Kg Cohort Of PRX-102 For Fabry Disease 9/9/2015
DelMar Pharmaceuticals Presents Updated Phase I/II Clinical Data On VAL-083 In Refractory Glioblastoma Multiforme At GBM2015 9/9/2015
Celsion (CLSN) Updates Clinical Trial Data and Slashes 20% of Workforce 9/9/2015
ORYZON Genomics Achieves Milestone In The Clinical Development Of ORY-1001 9/8/2015
Gordagen Confirms Bioavailability In Phase I Study For Evidence-Based Nutraceuticals 9/8/2015
Glenmark Pharmaceuticals's Novel Monoclonal Antibody GBR 830 To Enter Phase 2 Clinical Studies In Atopic Dermatitis And Celiac Disease In US And Europe 9/3/2015
Atopix Appoints Dr Andrew Zambanini As Chief Medical Officer 9/3/2015
Replicel Life Sciences Cleared To Initiate Clinical Trial Of RCS-01 For Dermal Rejuvenation 9/1/2015
Bionomics Limited (BNO.AX) Release: Successful BNC101 IND Submission Paves Way For Development Of Promising Cancer Stem Cell Drug Candidate 8/31/2015
Portage Biotech's PPL Will Advance Its Lead Candidate PPL-003 To An IND For Dry Eye Disease And Uveitis 8/31/2015
Novogen Limited (NVGN) Announces The Outcome Of A Comprehensive Science Review 8/31/2015
Genmab A/S (GEN.CO) Release: Data Published In The New England Journal of Medicine Shows Daratumumab Monotherapy Induced Durable Responses In Heavily Pre-Treated Relapsed Or Refractory Multiple Myeloma Patients 8/27/2015
Portage Biotech's Biohaven Doses First Human Subject In Phase 1 Trial With Lead Drug Candidate BHV-0223 8/27/2015
ORYZON To Present At Rodman & Renshaw 17th Annual Global Investment Conference 8/27/2015
Antibe Therapeutics Inc. (ATE.V) Reports Q1 2016 Interim Financial And Operating Results And A Further Update On Its Validation Studies 8/27/2015
Nordic Nanovector: Results For The Second Quarter And Half Year 2015 8/26/2015
Cardiome Pharma Corp. (COM.TO) Expands Partnership With Eddingpharm (Cayman) Inc. To Commercialize AGGRASTAT In China 8/24/2015
DelMar Pharmaceuticals To Present VAL-083 Lung Cancer Clinical Strategy At The 16th World Conference On Lung Cancer 8/24/2015
NMT Pharmaceuticals Singapore Announces Signing Of Letter Of Intent With CAO Pharmacueticals USA In Licensing And Development Of Anti-Cancer Drug CZ-48 8/24/2015
RedHill Biopharma Ltd. (RDHL) Announces Peer-Reviewed Publication Demonstrating Therapeutic Potential Of ABC294640 (YELIVA(TM)) In Prostate Cancer 8/24/2015
PharmaMar Announces License Agreement With Specialised Therapeutics Australia Pty For APLIDIN (plitidepsin) In Oncology 8/20/2015
BioLineRx Ltd. Reports Second Quarter 2015 Financial Results 8/20/2015
CytoDyn Release: First Self-Injectable HIV Antibody: 98% Success Rate In Phase 2b Clinical Trial, Could Be Commercial 8/18/2015
DelMar Pharmaceuticals Receives Additional Non-Dilutive Funding From NRC-IRAP To Support Expanded Research Program With Lead Product Candidate VAL-083 8/17/2015
3SBio Inc. (SSRX) Selected As A Constituent Of The Hang Seng Composite LargeCap & MidCap Index 8/17/2015
Hua Medicine’s Diabetes Drug Shows Efficacy In Phase Ic Trial 8/13/2015
Immunovaccine Inc. Announces Financial Results For Quarter Ended June 30, 2015 8/13/2015
BioLineRx Ltd. To Report Second Quarter 2015 Results On August 20, 2015 8/13/2015
Portage Biotech's Biohaven Raises $ 4.1 Million In First Tranche Of Private Placement. Portage Invests $ 2.5 Million 8/11/2015
Intec Pharma Ltd. Announces Closing of U.S. Initial Public Offering 8/10/2015
Regeneus (RGS.AX) (ASX:RGS) First Patient Treated In Progenza Stem Cell Trial For Knee Osteoarthritis 8/10/2015
Antibe Therapeutics Inc. (ATE.V) Announces Completion Of Phase I Studies Of ATB-346 And An Update On Its Validation Studies 8/10/2015
Pharmaxis (PXS.AX) And Synairgen plc Announce Research Collaboration To Develop LOXL2 Inhibitor For Pulmonary Fibrosis 8/5/2015
BeiGene Co.,Ltd Receives Approval To Initiate Clinical Trials In China With BGB-283 For Solid Tumor Cancers 8/3/2015
Suzhou Connect Reports Positive Results For Trial Of Autoimmune Drug 7/30/2015
Kyowa Hakko Kirin And Bristol-Myers Squibb (BMY) Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab And Opdivo (Nivolumab) In Advanced Solid Tumors In The U.S. 7/30/2015
GlaxoSmithKline (GSK) CEO Confident Investors Will Be Pleased With Pipeline on Nov. R&D Day 7/30/2015
Medivir (MVRBF) Announces Start Of A Phase I Clinical Trial Of The Nucleotide Polymerase Inhibitor AL-704 For Treatment Of Hepatitis C 7/29/2015
Cardiome Pharma Corp. (COM.TO) Partner Eddingpharm (Cayman) Inc. To Initiate BRINAVESS Phase I Study In China 7/24/2015
ANGLE plc Preliminary Results For The Year Ended 30 April 2015 7/23/2015
Beike Bio-Technology Co. Ltd Publishes New Research Finding Adult Mesenchymal Stem Cells Safe And Effective In Acute Myocardial Infarction 7/21/2015
MGB Biopharma Limited Commences Phase I Clinical Trial With Oral Formulation Of MGB-BP-3 For The Treatment Of Multi-Resistant Clostridium Difficile Infections 7/21/2015
Peritech Pharma’s Novel Hemorrhoids Treatment Shown Superior To Preparation-H In Pivotal Trial 7/21/2015
OrbusNeich Announces Enrollment Of First Patient In China Recovery Study 7/20/2015
DelMar Pharmaceuticals Expands GBM Clinical Trial With Fifth Clinical Trial Site Added In Denver, Colorado 7/20/2015
THERAVECTYS To Present Detailed Phase I/II Results From The First-Ever Lentiviral-Vector Based Therapeutic Vaccine Trial At The 2015 Towards An HIV Cure Symposium 7/20/2015
InnaVirVax Presents Highly Encouraging Results Of Its First Clinical Study On VAC-3S Immunotherapy For HIV 7/20/2015
BeiGene Co.,Ltd Doses First Patient In Phase Ib Study Of BGB-283, A Novel Second Generation B-RAF Inhibitor 7/14/2015
Adocia Initiates Two Clinical Studies On Its Combination Of Long-Acting Insulin Glargine And Fast-Acting Insulin Lispro, Biochaperone Combo 7/10/2015
BIO2015 EXCLUSIVE: BioSpace (DHX)’s Insider Profile of Neovacs SA 7/9/2015
AXON Neuroscience’s Vaccine To Halt Alzheimer’s Finishes Phase 1 Clinical Trial 7/8/2015
Curetis Initiates Next Phase Of Unyvero U.S. FDA Trial In Lower Respiratory Tract Infections 7/8/2015
Enzymotec Announces Investigator Initiated Clinical Trial Of Vayarin In Managing ADHD In Children With Epilepsy 7/7/2015
PhytoTech Medical Ltd (ASX:PYL) Oral Formulations Advance Towards Phase 1 Clinical Trials 7/6/2015
Avexxin Completes Phase I/IIA Study In Psoriasis And Achieves Proof-Of-Concept In Man With Its Compound AVX001 In A Topical Formulation 7/2/2015
Replicel Life Sciences Enrolls First Participant In Phase 1/2 Clinical Trial Of RCT-01 For Chronic Achilles Tendinosis 6/30/2015
RedHill Biopharma Ltd. (RDHL) Initiates Phase I/II Study Of ABC294640 For Refractory Lymphoma 6/29/2015
Bioiberica To Trial A New Compound On Human Subjects That Prevents Memory Loss In Patients With Mild Alzheimer's 6/29/2015
ProQR Therapeutics B.V. (PRQR) Announces Enrollment Has Started In Global Phase 1b Study Of QR-010 In Cystic Fibrosis Patients 6/26/2015
RestorGenex Announces Prostate Cancer Data On RES-529, A Dual TORC1/TORC2 Inhibitor 6/23/2015
Heptares Announces Positive Outcome Of Phase 1A Study With First-Ever Selective Muscarinic M1 Receptor Agonist For Improving Cognition In Patients With Alzheimer's Disease 6/17/2015
Prothena (PRTA) Presents Clinical Results Demonstrating Robust, Rapid Reduction In Levels Of Free Serum Alpha-Synuclein Of Up To 96% After Single Dose Of PRX002, Novel Protein Immunotherapy For Parkinson's Disease 6/17/2015
Neovacs SA Initiates Clinical Program In Dermatomyositis 6/16/2015
Laurent Pharmaceuticals Announces Positive Phase 1b Topline Results For LAU-7b In Cystic Fibrosis 6/15/2015
Amarillo Biosciences (AMAR) Announces Presentation Of Eltoprazine Phase I/IIa Clinical Data At The 19th International Congress Of Parkinson's Disease And Movement Disorders 6/15/2015
Prothena (PRTA)'s NEOD001 Protein Immunotherapy Clinical Data Highlighted In Oral Presentation At The 20th Congress Of The European Hematology Association 6/12/2015
BerGenBio AS Initiates NSCLC Clinical Trial With BGB324 In Combination With erlotinib 6/10/2015
Prothena (PRTA) Announces First Human Dosed In Phase I Study Of PRX003 For The Treatment Of Psoriasis And Other Inflammatory Diseases 6/10/2015
FDA Awards Isarna Therapeutics Orphan Drug Designation For ISTH0036 To Improve Glaucoma Treatment Outcome 6/10/2015
Merck's KEYTRUDA (pembrolizumab) Receives Conditional Approval In Canada For The Treatment Of Advanced Melanoma 6/8/2015
BeiGene Co.,Ltd Enrolls First Patient In Phase I Study Of BGB-A317, A Humanized Anti-PD-1 Monoclonal Antibody 6/8/2015
Prothena (PRTA) To Present Clinical Results From Its Phase I Single Ascending Dose Study Of PRX002 At 19th International Congress Of Parkinson's Disease And Movement Disorders 6/8/2015
ASCO15: Prothena (PRTA) Presents Compelling New Data From Ongoing Phase I/II Study Of NEOD001 In Patients With AL Amyloidosis At 2015 ASCO Annual Meeting 6/2/2015
Aptose Biosciences Granted Orphan Drug Designation By The U.S. FDA For APTO-253 In Acute Myeloid Leukemia 6/2/2015
ASCO15: Adaptimmune Announces Data From Clinical Studies Of NY-ESO-1 Specific T-Cells In Multiple Cancers At The 2015 Annual ASCO Meeting 6/1/2015
ASCO15: VBL Therapeutics (VBLX) To Present Phase I/IIa Data From VB-111 In Recurrent Platinum-Resistant Mullerian Cancer At The 2015 ASCO Annual Meeting 6/1/2015
BerGenBio AS Release: BGB324 And BGB10C9 Show Promise In Models Of Pancreatic Cancer 6/1/2015
ASCO15: Targovax Releases TGO1 RAS-Mutation-Specific Immunotherapy Data At ASCO 6/1/2015
ASCO15: Hanmi Pharma ‘HM61713’ Demonstrated The Effect Of Tumor Volume Reduction 6/1/2015
Synageva BioPharma (GEVA) Submits Kanuma (Sebelipase Alfa) Application For LAL Deficiency In Japan 5/27/2015
Alizé Pharma Presents Clinical Results From The AZP-531 Program At The American Diabetes Association 75th Scientific Sessions 5/26/2015
R-Tech Ueno: Announcement On Completion Of The Phase I Single-Dose Clinical Trial for the Novel VAP-1 Inhibitor RTU-1096 5/26/2015
e-Therapeutics plc Release: Progress In ETS2101 Phase Ib Study 5/21/2015
Isarna Therapeutics Announces Orphan Drug Designation In The European Union For ISTH0036 To Treat Advanced-Stage Glaucoma 5/21/2015
Prothena (PRTA) Announces Presentation Of Clinical Data From The Ongoing Phase I/II NEOD001 Study And Systemic Amyloidosis Patient Survey Results At 20th Congress Of The European Hematology Association 5/21/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Phase 1 Study In Pediatric Patients With Brain Tumors 5/19/2015
Significant Progress For Pluristem Therapeutics (PSTI): PLX Cells Were Selected For European Medicines Agency's Adaptive Pathways Pilot Project 5/18/2015
TopiVert Starts Phase I Clinical Trial In Ulcerative Colitis 5/14/2015
Oxford University, GlaxoSmithKline (GSK) And Emergent BioSolutions (EBS) Announce Initiation Of A Prime Boost Study Of Ebola Vaccine Candidates 5/13/2015
Bavarian Nordic (BAVA.CO) Announces Presentation Of Preliminary Phase 1 Results For The Ebola Prime-Boost Vaccine Regimen Of MVA-BN Filo And Janssen Pharmaceutical's AdVac Technology 5/13/2015
Drawbridge Pharmaceuticals Moves Phaxan Forward 5/4/2015
Basilea Pharmaceutica (BSLN.SW) Reports Start Of First-In-Human Phase I Oncology Study With Oral Panraf Kinase Inhibitor 5/4/2015
Ascendis Pharma A/S Announces Results Of Phase 1 Study Of Transcon Treprostinil 4/29/2015
GW Pharmaceuticals (GWPH) Receives Orphan Drug Designation From FDA For Cannabidiol For The Treatment Of Neonatal Hypoxic-Ischemic Encephalopathy 4/24/2015
Nordic Nanovector: Results Of Phase 1 Study Of Betalutin In Patients With Non-Hodgkin Lymphoma To Be Presented At The International Conference On Malignant Lymphoma 4/23/2015
Cardio3 Biosciences Announces Infusion Of First Patient In NKG2D Phase I Trial With No Short Term Adverse Events 4/20/2015
AstraZeneca PLC (AZN)'s Experimental Lung Cancer Drug Delays Disease By More Than a Year 4/20/2015
cCam Biotherapeutics Announces Initiation Of Phase 1 Trial Of CM-24, A Novel Immune Checkpoint Inhibitor For Cancer Immunotherapy 4/20/2015
OncoMed Pharmaceuticals, Inc. (OMED) Presents Demcizumab Data From Phase 1b Clinical Trial In Non-Small Cell Lung Cancer Patients At The European Lung Cancer Conference 4/16/2015
Isarna Therapeutics Initiates First-In-Human Phase I Trial For ISTH0036 To Treat Advanced Glaucoma 4/16/2015
Suven Life Sciences Ltd Initiated Multiple Ascending Dose (MAD) Studies In Phase 1 Clinical Trial For Their Investigational Compound SUVN-G3031 4/13/2015